Table 6.
Comparison of baseline characteristics between TNF-i with MTX (n = 40) and TNF-i without MTX (n = 9)
| Variables | TNF-i without MTX (n = 9) | TNF-i with MTX (n = 40) | *P value |
|---|---|---|---|
| Male, n (%) | 1 (11.1%) | 11 (27.5%) | 0.4203 |
| Age (years) | 43.7 ± 16.0 | 40.8 ± 13.7 | 0.2659 |
| Disease duration (entero-BD, months) | 54.0 ± 54.7 | 52.1 ± 63.5 | 0.5520 |
| Multiple ulceration, n (%) | 5/9 (55.6%) | 27/40 (67.5%) | 0.7001 |
| History of relapse, n (%) | 7/9 (77.8%) | 22/40 (55.8%) | 0.2771 |
| History of perforation, n (%) | 0/9 (0%) | 9/40 (22.5%) | 0.1795 |
| History of surgery, n (%) | 0/9 (0%) | 6/40 (15.0%) | 0.5765 |
| Concomitant CS use, n (%) | 6/9 (66.7%) | 23/40 (57.5%) | 0.7199 |
| Concomitant CS dose (mg/day) | 2.22 ± 3.63 | 8.83 ± 17.2 | 0.4414 |
| DAIBD at baseline | 61.1 ± 23.3 | 65.5 ± 37.3 | 0.8361 |
Plus-minus values are means ± standard deviation.*P < 0.05 by Fisher’s exact test or Mann–Whitney U test. BD Behcet’s disease, CS corticosteroid, col colchicine, MS mesalazine, SSZ sulfasalazine, MTX methotrexate, AZ azathioprine, TNF-i TNF inhibitors, DAIBD disease activity index for intestinal Behcet’s disease